Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the MAPK pathway, the PI3K/AKT pathway primarily regulates cell survival, metabolism, growth, and drug resistance [10,11].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although BEZ235 showed satisfactory antitumor activity against various cancer types in a preclinical model, poor tolerability and high adverse events were observed in clinical trials38–41.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 1×
“Class 1 PI3K family members that convert phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) thereby activating AKT via two crucial phosphorylation events at threonine 308 catalyzed by phosphoinositide-dependent kinase-1 (PDK1) and at serine 473 catalyzed by mammalian target…”
BackgroundMammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558 · cited 1×
“mTORC1 has been shown to regulate cell growth by controlling mRNA translation initiation and to regulate ribosome biogenesis, autophagy and lipid biosynthesis [34].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Coexisting mutations of the PIK3CA, which occur in about 8%–9% of CRC cases [25,26], have also been implicated in the resistance of KRAS mutated CRC cells to MEK inhibition [27,28].”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · cited 1×
“Genetic anomalies of PI3K pathway components, such as PTEN loss, PI3K amplification/mutation, AKT mutation or RTK activation, result in activation of this pathway leading to tumorigensis [3].”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328 · cited 1×
“RAS and RAF gene mutations have been considered potential markers of sensitivity to MEK inhibition largely due to the constitutive activation of MEK seen in BRAF mutant cancer cells and to a lesser extent in KRAS mutant cells [17,18].”
BackgroundThe insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124 · cited 1×
“Insulin-like growth factor-1 receptor (IGF-1R) is a key activator of these two pro-survival signaling pathways [1].”
BackgroundThe PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878 · cited 1×
“mTOR inhibition has been correlated with activation of MAPK pathway through PI3K’s activation of RAS [42].”
BackgroundPhosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677 · cited 1×
“Activated MEK phosphorylates its only substrate ERK1/2 leading to dimerization, nuclear translocation and induction of target genes [5,6].”
Background
Cited by
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
“Mutation of the p53 gene or deletion of the 17p chromosome is significant for tumor initiation, especially from adenoma to carcinoma in CRC [157,158]. p53 inhibits mTOR activity via AMPK-β1 and TSC2 in CRC cell lines. p53 also regulates the mTOR pathway by a target gene, DNA damage and development 1 (REDD1), which is…”
BackgroundInfluentialSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9807 · Cited by 360
Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177
“Combinations of agents targeting distinct RAS effector pathways are currently under clinical investigation, and it remains to be seen whether these combinations will be tolerated at doses that may provide therapeutic benefit (10, 11).”
BackgroundSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
The current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.001 · Cited by 155
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Sanchez, J., Wang, T., & Cohen, M. S. (2018) · Drugs · doi:10.1007/s40265-018-0884-8 · Cited by 155
“There is a breadth of preclinical and clinical data supporting this approach [108, 109].”
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Desai, J., Gan, H., Barrow, C., Jameson, M., Atkinson, V., Haydon, A., Millward, M., Begbie, S., Brown, M., Markman, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02654 · Cited by 115
“In melanoma, resistance to first-generation B-RAF inhibitors stems from several mechanisms, including epidermal growth factor receptor (EGFR)–mediated reactivation of MAPK signaling,(18) RAS-independent RAF kinase dimerization induced by B-RAF splice variants,(19,20) AKTdependent signaling pathways,(17,21) and MAPK-re…”
BackgroundTea polyphenols and their chemopreventive and therapeutic effects on colorectal cancer
Wang, S.-T., Cui, W., Pan, D., Jiang, M., Chang, B., & Sang, L.-X. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i6.562 · Cited by 128
Park, Y., Kim, H., Cho, Y., Min, D., Cheon, S., Lim, Y. J., Song, S., Kim, S. J., Han, S., Park, K. J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31662 · Cited by 66
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw209 · Cited by 68
Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy
Cuomo, F., Altucci, L., & Cobellis, G. (2019) · Cancers · doi:10.3390/cancers11101465 · Cited by 65
“Cancer cell proliferation in RAS- and/or RAF-mutated tumors is maintained by increased autophagy [32,33].”
BackgroundYang, Y., Wang, T., Chen, D., Ma, Q., Zheng, Y., Liao, S., Wang, Y., & Zhang, J. (2018) · Cell Biology International · doi:10.1002/cbin.11055 · Cited by 63
“It can activate the mechanistic target of rapamycin pathway, which is a master regulator of cell growth, protein translation and other macromolecule synthesis (Temraz et al., 2015), and can directly inhibit apoptosis (Li et al.”
BackgroundUrsolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer
Shan, J., Xuan, Y., Zhang, Q., Zhu, C., Liu, Z., & Zhang, S. (2016) · Protein & Cell · doi:10.1007/s13238-016-0295-0 · Cited by 63
“…anomalies of the phosphatidylinositol-3 kinase (PI3K) pathway, such as PI3K amplification/mutation, AKT mutation, or PTEN loss, result in activation of this pathway, leading to tumorigenesis and have been implicated in the resistance of KRAS mutant CRC cells to MEK inhibition (Temraz et al., 2015).”
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Mondal, K., Posa, M. K., Shenoy, R. P., & Roychoudhury, S. (2024) · Cells · doi:10.3390/cells13141221 · Cited by 69
“Preclinical studies of KRAS - and BRAF -mutated CRC noticed the necessity of dual inhibition of MEK and PIK3CA pathways in the animal model of cancer [90].”
BackgroundNam, S. K., Yun, S., Koh, J., Kwak, Y., Seo, A. N., Park, K. U., Kim, D.-W., Kang, S.-B., Kim, W. H., & Lee, H. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151865 · Cited by 56
Zhou, S., Xu, H., Tang, Q., Xia, H., & Bi, F. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0413 · Cited by 53
“Therefore, targeting the downstream substrate MEK in KRAS-, BRAF-, or NRAS-mutant tumors is a major and potential strategy in colon cancer (26).”
BackgroundThe role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Wang, H., Tang, R., Ling, J., & Jia, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1494802 · Cited by 65
Bartnik, M., Sławińska-Brych, A., Żurek, A., Kandefer‐Szerszeń, M., & Zdzisińska, B. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.06.010 · Cited by 50
New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective
Sestito, S., Runfola, M., Tonelli, M., Chiellini, G., & Rapposelli, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00874 · Cited by 46
“In regards of the horizontal strategy, the dual targeted inhibition of MEK and PI3K pathway effectors promises to be a valid strategy to overcome resistance to MEK inhibitor therapy in metastatic colorectal cancer, which is characterized by a frequent perturbation of the MAPK and PI3K signaling axis (Temraz et al., 20…”
BackgroundHasan, M., Marzouk, M. A., Adhikari, S., Wright, T. D., Miller, B. P., Matossian, M. D., Elliott, S. G., Wright, M. K., Alzoubi, M. S., Collins‐Burow, B. M., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.116202 · Cited by 44
“The involvement of MEK1/2, MEK5, and PI3K in C4- or C5-mediated anticancer actions was chosen because of their involvement in MT1R or ESR1-mediated BC signaling (Grant et al., 2009; Temraz et al., 2015; Simoes et al., 2016; Araki and Miyoshi, 2018; Kastrati et al., 2017; Martinelli et al., 2017; Kumar et al., 2018).”
BackgroundInfluentialMa, W., Zhang, Q., Li, X., Ma, Y., Liu, Y., Hu, S., Zhou, Z., Zhang, R., Du, K., Syed, A., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105464 · Cited by 38
Hajjafari, A., Sadr, S., Rahdar, A., Bayat, M., Lotfalizadeh, N., Dianaty, S., Rezaei, A., Moghaddam, S. P., Hajjafari, K., Simab, P. A., et al. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.112409 · Cited by 39
Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells
Park, J., Lee, G.-E., An, H.-J., Lee, C., Cho, E. S., Kang, H. C., Lee, J. Y., Lee, H. S., Choi, J., Kim, D. J., et al. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01358-y · Cited by 37
“Moreover, prolonged drug treatment increases abundance of the oncogenic driver, resulting in increased flux through the ERK pathway and restoration of ERK activity above the threshold required for cell growth (Poulikakos and Solit 2011; Temraz et al. 2015).”
BackgroundMoon, J.-H., Hong, S., Kim, J. E., Shin, J.-S., Kim, J.-S., Jung, S.-A., Ha, S. H., Lee, S., Kim, J., Lee, D. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0434-5 · Cited by 36
Wu, C.-S., Wu, S., Chen, H.-C., Chu, C., Tang, H. F., Liu, H., Hong, Y., Huang, C. F., Huang, G.-C., & Su, C. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108227 · Cited by 37
Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
Kochetkova, E. Y., Blinova, G. I., Bystrova, O. A., Martynova, M. G., Pospelov, V. A., & Pospelova, T. V. (2017) · Aging · doi:10.18632/aging.101325 · Cited by 36
“Nevertheless, several works performed on M229 R5, M238 R1 and M14 melanoma cells and on Ki-Ras-mutated colorectal cancer cell lines show that these cells are able to acquire the resistance to MEK/ERK suppression [59].”
BackgroundNeomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 35
Fritsche‐Guenther, R., Zasada, C., Mastrobuoni, G., Royla, N., Rainer, R. J., Roßner, F., Pietzke, M., Klipp, E., Sers, C., & Kempa, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-27394-1 · Cited by 36
Geißler, A.-L., Geissler, M., Kottmann, D., Lutz, L., Fichter, C. D., Fritsch, R., Weddeling, B., Makowiec, F., Werner, M., & Laßmann, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15211 · Cited by 32
“Indeed, combination of mutations in these downstream signaling pathways were shown to influence direct (B)RAF inhibition [51, 52] rather than EGFR-targeted therapy.”
BackgroundGibson, W. J., Ruan, D. T., Paulson, V., Barletta, J. A., Hanna, G. J., Kraft, S., Calles, A., Nehs, M. A., Moore, F. D., Taylor-Weiner, A. N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2154-t · Cited by 32
“On the basis of these data, MAPK/PI3K combination therapy is being evaluated in several early-stage clinical combination therapy trials in multiple tumor types, including melanoma and colorectal cancer (24).”
MethodMioc, M., Avram, S. I., Bercean, V. N., Kurunczi, L., Ghiulai, R. M., Oprean, C., Coricovac, D. E., Dehelean, C. A., Mioc, A., Bălan, M., et al. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00373 · Cited by 33
“The main drawback in the development of targeted therapy is that when a single signaling pathway is inhibited, cancer survival may still be ensured through the consecutive activation of alternative signaling pathways (Temraz et al., 2015).”
BackgroundRambur, A., Lours-Calet, C., Beaudoin, C., Buñay, J., Vialat, M., Mirouse, V., Trousson, A., Renaud, Y., Lobaccaro, J. A., Baron, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16123-w · Cited by 30
Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models
Stulpinas, A., Sereika, M., Vitkevičienė, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1045521 · Cited by 36
Béraud-Dufour, S., Devader, C., Massa, F., Roulot, M., Coppola, T., & Mazella, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111860 · Cited by 29
Novel Perspectives in Pseudomyxoma Peritonei Treatment
Sommariva, A., Tonello, M., Rigotto, G., Lazzari, N., Pilati, P., & Calabrò, M. L. (2021) · Cancers · doi:10.3390/cancers13235965 · Cited by 31
“A dual pathway inhibition in patients with advanced tumors exhibited good efficiency but great toxicity [60,61].”
BackgroundIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yu, Y., Hall, T. G., Eathiraj, S., Wick, M. J., Schwartz, B. E., & Abbadessa, G. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000486 · Cited by 28
Huang, Z., Liu, M., Li, D., Tan, Y., Zhang, R., Xia, Z., Wang, P., Jiao, B., Liu, P., & Ren, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011060 · Cited by 30
“Targeting the KRAS effector signaling pathways could also prove efficacious in treating tumors with KRAS mutations, as the inhibitors have entered clinical trials demonstrating promising clinical activity in KRAS mutant tumor (17, 18).”
BackgroundAtanasova, V. S., Riedl, A., Strobl, M. M., Flandorfer, J., Unterleuthner, D., Weindorfer, C., Neuhold, P., Stang, S., Hengstschläger, M., Bergmann, M. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021668 · Cited by 30
“increased efficacy of PI3K/MAPK pathway combinatorial inhibition is achieved at the expense of augmented toxicity [40].”
BackgroundAnti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 30
Amaral, T. M. S., Niessner, H., Sinnberg, T. W., Thomas, I., Meiwes, A., Garbe, C., Garzarolli, M., Rauschenberg, R., Eigentler, T., & Meier, F. E. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa140 · Cited by 27
Sapir, T., Shifteh, D., Pahmer, M., Goel, S., & Maitra, R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0745 · Cited by 28
“Inhibition of MEK, especially in combination with BRAF inhibitors, has seen success in treating various cancers, although some limitations do exist (61, 62).”
Hirashita, Y., Tsukamoto, Y., Yanagihara, K., Fumoto, S., Hijiya, N., Nakada, C., Uchida, T., Matsuura, K., Kodama, M., Okimoto, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13094 · Cited by 28
Li, Y., Dong, Q., & Cui, Y. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0137 · Cited by 29
Yousef, A. I., El-Masry, O. S., & Abdel-Mohsen, M. A. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.743 · Cited by 26
“Among the downstream effectors signaling are the RAF/MEK/ERK and the PI3K/Akt pathways (Phipps et al., 2013; Temraz et al., 2015).”
BackgroundLung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis
Yang, S., Xia, J., Yang, Z., Xu, M., & Li, S. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100311 · Cited by 24
Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0735 · Cited by 24
“These combination treatments are mainly based on MEK inhibitors (12, 13).”
BackgroundYu, Z., Chen, Z., Su, Q., Ye, S., Yuan, H., Kuai, M., Lv, M., Tu, Z., Yang, X., Liu, R., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.028 · Cited by 23
Defining subpopulations of differential drug response to reveal novel target populations
Keshava, N., Toh, T. S., Yuan, H., Yang, B., Menden, M. P., & Wang, D. Y. Q. (2019) · npj Systems Biology and Applications · doi:10.1038/s41540-019-0113-4 · Cited by 24
Lee, H., Son, E., Lee, K., Lee, Y., Kim, Y., Lee, J.-C., Lim, Y., Hur, M., Kim, D., & Nam, D.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235894 · Cited by 22
“When the oncogenic stimulus occurs downstream, such as in tumors with KRAS mutations, resistance to these therapies arises [4,5,7,12,16,39,40].”
BackgroundHJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
Jiang, X., Wu, M., Xu, Z., Wang, H., Wang, H., Yu, X., Li, Z., & Teng, L. (2018) · Cancer Management and Research · doi:10.2147/cmar.s188364 · Cited by 22
Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo
Hicks, H. M., McKenna, L. R., Espinoza, V. L., Pozdeyev, N. V., Pike, L. A., Sams, S. B., LaBarbera, D. V., Reigan, P., Raeburn, C. D., & Schweppe, R. E. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23284 · Cited by 21
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 18
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
Cutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410919 · Cited by 23
Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy
Chang, R. Y., Tosi, U., Voronina, J. C., Adeuyan, O. O., Wu, L. Y., Schweitzer, M. E., Pisapia, D. J., Becher, O. J., Souweidane, M. M., & Maachani, U. B. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz004 · Cited by 22
“48,49 These findings are consistent with the results of both preclinical work and clinical trial results demonstrating the safety of CED in DIPG patients, and emphasize the strengths of a local delivery approach in the treatment of brain malignancies.”
Henderson, R., French, D., Sullivan, R. J., Maughan, T., Clarke, M. J., & Lawler, M. (2019) · Oncotarget · doi:10.18632/oncotarget.26909 · Cited by 24
“Tumours harbouring mutated forms of these genes are resistant to anti-epidermal growth factor receptor (EGFR) therapy [28].”
BackgroundQu, G., Shi, M., Wang, D., Wu, J., Wang, P., Gong, M., & Zhang, Z. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01571-x · Cited by 18
“In contrast, a combined blockade of both pathways with MEK162 and BKM120 overcame the reciprocal pathway activation and resulted in a significant tumor growth inhibition [17, 19, 25].”
BackgroundGoulielmaki, M., Assimomytis, N., Rožanc, J., Taki, E., Christodoulou, I., Alexopoulos, L. G., Zoumpourlis, V. C., Pintzas, A., & Papahatjis, D. P. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.005 · Cited by 20
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
Tokumaru, Y., Takabe, K., Yoshida, K., & Akao, Y. (2020) · Cancer Science · doi:10.1111/cas.14357 · Cited by 18
Huang, T., Wu, S., Huang, Y.-J., Wei, P., Wu, A. T. H., & Chao, T.-Y. (2017) · Europe PMC (PubMed Central) · Cited by 19
Maruyama, K., Shimizu, Y., Nomura, Y., Oh-hara, T., Takahashi, Y., Nagayama, S., Fujita, N., & Katayama, R. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00793-6 · Cited by 16
Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
Chauhan, A., Semwal, D. K., Satyendra, M., Goyal, S. K., Marathe, R., & Semwal, R. B. (2016) · Medical Sciences · doi:10.3390/medsci4040016 · Cited by 16
“cancer and esophageal cancer [125], whereas a combination of Everolimus, vinorelbine and trastuzuma is being used in phase III randomized trials of mTOR inhibitors in metastatic breast cancer [126].”
BackgroundIn Vitro Toxicity of Asparagus Saponins in Distinct Multidrug‐Resistant Colon Cancer Cells
Jaramillo, S., Guillén, R., Jiménez‐Araujo, A., Rodríguez‐Arcos, R., & López, S. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800282 · Cited by 16
High-throughput detection of clinically targetable alterations using next-generation sequencing
Vendrell, J. A., Grand, D., Rouquette, I., Costes, V., Icher, S., Sèlves, J., Larrieux, M., Barbe, A., Brousset, P., & Solassol, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15875 · Cited by 16
“Clinical trials of dual targeted inhibition of MEK and the PIK3CA/AKT/mTOR pathway in patients with concomitant mutations of genes belonging to these pathways are also underway (for review, [32]).”
Mazella, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911888 · Cited by 17
“The activation of the phosphatidylinositol 3-kinase (PI3 kinase) pathway is an important step to induce calcium release from the intracellular stores (for a review, see [61]), a pathway involved in the development of colorectal cancers [62].”
BackgroundLoureiro, G., Kerbauy, D. M. B., Lee, M. L. D. M., de Souza, M. P., Kimura, E. Y. S., Rezende, D. C., Silva, M. C. D. A., Chauffaille, M. D. L. L. F., & Yamamoto, M. (2023) · Cancer Reports · doi:10.1002/cnr2.1912 · Cited by 27
“9 One signal that is overactivated in a wide range of tumor types is the production of a phospholipid, phosphatidylinositol triphosphate, by phosphatidylinositol 3-kinase (PI3K).”
BackgroundMEK is a promising target in the basal subtype of bladder cancer
Merrill, N. M., Vandecan, N. M., Day, K. C., Palmbos, P. L., Day, M. L., Udager, A. M., Merajver, S. D., & Soellner, M. B. (2020) · Oncotarget · doi:10.18632/oncotarget.27767 · Cited by 15
Wang, H., Chi, L., Yu, F., Dai, H., Si, X., Gao, C., Wang, Z., Liu, L., Zheng, J., Ke, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116922 · Cited by 17
Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 16
Hon, K. W., Nag, S., Stany, B. K., Mishra, S., & Naidu, R. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106313 · Cited by 14
Valdeira, A. S. C., Ritt, D. A., Morrison, D. K., McMahon, J. B., Gustafson, K. R., & Salvador, J. A. R. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00434 · Cited by 14
“HT29 cells have also shown resistance to the B-RafV600E selective inhibitor PLX4720 as previously reported (Oikonomou et al., 2011; Temraz et al., 2015).”
BackgroundHoang, V. T., Matossian, M. D., La, J., Hoang, K., Uçar, D. A., Elliott, S. G., Burks, H. E., Wright, T. D., Patel, S., Bhatt, A. B., et al. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29916 · Cited by 14
Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168)
Dort, M. E. V., Galbán, S., Nino, C. A., Hong, H., Apfelbaum, A. A., Luker, G. D., Thurber, G. M., Atangcho, L., Besirli, C. G., & Ross, B. D. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00111 · Cited by 13
Dort, M. E. V., Jang, Y., Bonham, C. A., Heist, K., Palagama, D. S. W., McDonald, L., Zhang, E. Z., Chenevert, T. L., Luker, G. D., & Ross, B. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113996 · Cited by 12
Xu, K., Zhang, Y., Han, B., Bai, Y., Xiong, Y., Song, Y., & Zhou, L. (2017) · Tumor Biology · doi:10.1177/1010428317705504 · Cited by 13
Jin, Q., Jiao, W., Lian, Y., Chitrakar, B., Sang, Y., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1367417 · Cited by 13
“(Martin et al., 2013; Valtorta et al., 2013; Temraz et al., 2015; Mármol et al., 2017).”
Tan, Y. Q., Sun, B., Zhang, X., Zhang, S., Guo, H., Basappa, B., Zhu, T., Sethi, G., Lobie, P. E., & Pandey, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06551-7 · Cited by 11
“…dual inhibition of both p44/42 MAPK and PI3K/AKT pathways has been shown to potentially overcome resistance, and achieve optimal cellular and xenograft growth inhibition [32, 33, 56, 59], the therapeutic potential of concurrently targeting these critical effector pathways has been widely explored.”
Rationalizing Drug Response in Cancer Cell Lines
Juan-Blanco, T., Duran‐Frigola, M., & Aloy, P. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.03.021 · Cited by 17
Willis, J. E., Temple‐Smolkin, R., Sargent, D. J., Colasacco, C., Minsky, B. D., Sepulveda, A. R., Hamilton, S. R., Singh, V., Monzon, F. A., Grody, W. W., et al. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vf3q-g225 · Cited by 10
The safety and efficacy of binimetinib for lung cancer: a systematic review
Zahmatyar, M., Kharaz, L., Jahromi, N. A., Jahanian, A., Shokri, P., & Nejadghaderi, S. A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03178-4 · Cited by 9
Sabt, A., Tawfik, H. O., Khaleel, E. F., Badi, R. M., Ibrahim, H. A. A., Elkaeed, E. B., & Eldehna, W. M. (2024) · Molecular Diversity · doi:10.1007/s11030-023-10777-6 · Cited by 9
“10, demonstrated a strong effect against K-RAS and B-RAF by inhibiting the connection between RAS and MEK-ERK signaling in vitro and in vivo [139].”
Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth
Bäumer, N., Rehkämper, J., Appel, N., Terheyden, L., Hartmann, W., Wardelmann, E., Buchholz, F., Müller‐Tidow, C., Berdel, W. E., & Bäumer, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200163 · Cited by 9
Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
Machmouchi, A., Chehade, L., Temraz, S. N., & Shamseddine, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11030678 · Cited by 8
“revealed that activation of ASK-1 and p38 pathway was induced by L-ascorbic acid and cetuximab in SVCT-2 expressing cells [47].”
BackgroundSelf-citationTelechea‐Fernández, M., Rodríguez‐Fernández, L., García, C., Zaragozá, R., Vinã, J. R., Cervantes, A. M. R., & García–Trevijano, E. R. (2018) · Oncotarget · doi:10.18632/oncotarget.23888 · Cited by 8
“Dual targeted inhibition of both pathways is required for the effective blocking of mutated KRAS and PI3K downstream effects [33].”
van Bentum, M., Klinger, B., Sieber, A., Naghiloo, S., Zauber, H., Lehmann, N., Haji, M., Niquet, S., Mertins, P., Blüthgen, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59404-y · Cited by 8
Liu, R., Chen, Z., Hu, G., Yu, Z., Li, Q., Liu, D., Li, L., & Liu, Z. (2023) · Pharmaceuticals · doi:10.3390/ph16020244 · Cited by 7
Aramini, B., Masciale, V., Banchelli, F., D’Amico, R., Dominici, M., & Haider, K. H. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94840 · Cited by 11
“Currently, several clinical trials employing the inhibition of PI3KCA, MEK, and PTEN are in progress [26].”
BackgroundOcular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors
Smith, A. J. H., Pawar, M. D., Dort, M. E. V., Galbán, S., Welton, A. R., Thurber, G. M., Ross, B. D., & Besirli, C. G. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0126 · Cited by 5
Report and Application of a Tool Compound Data Set
Butler, K. V., MacDonald, I. A., Hathaway, N. A., & Jin, J. J. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00343 · Cited by 5
Chen, J.-S., Enwolo-Chibueze, C. G., Chinyama, H. A., Lai, C.-T., Ezeala, I. C., Huang, P.-Y., Wu, A. T. H., & Huang, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188780 · Cited by 4
“Current single-target therapies rarely produce lasting responses, emphasizing the need for multi-targeted strategies [12–18].”
Vuaroqueaux, V., Musch, A., Peille, A.-L., Kelter, G., Weichert, L., Metz, T., Hendriks, H. R., & Fiebig, H. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0221 · Cited by 4
“TheuseofMEKinhibitors incombination with other anticancer agents, such as PI3K/AKT, EGFR, mitotic inhibitors, and immunomodulatory drugs, appears to be more promising and is being increasingly studied (27–31).”
BackgroundCutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G. T., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202410919 · Cited by 6
Liu, R., Yu, Z., Chen, Z., Liu, D., Huang, F., Li, Q., Hu, G., Yi, X., Li, X., Zhou, H., et al. (2020) · PeerJ · doi:10.7717/peerj.9981 · Cited by 4
LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11
Imai, H., Saijo, K., Chikamatsu, S., Kawamura, Y., & Ishioka, C. (2020) · Cancer Science · doi:10.1111/cas.14759 · Cited by 4
Hou, H., Liu, D., Zhang, C., Jiang, Y., Lu, G., Zhou, N., Yang, X., Zhang, X., Li, Z., Zhu, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21349 · Cited by 3
“Preclinical data supported dual targeted inhibition of MEK and one or more of the PI3K/AKT pathway effectors in metastatic CRC, which was superior to a single agent alone [34].”
Shyshkin, M. A. (2018) · Pathologia · doi:10.14739/2310-1237.2018.1.129447 · Cited by 3
The Endeavours in RAS Inhibition - the Past, Present, and Future
Hussain, J., Kirubakaran, S., & Ravi, S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200903163044 · Cited by 4
Metadata
- Authors
- Temraz, S., Mukherji, D., & Shamseddine, A.
- Affiliations
- American University of Beirut Medical Center (LB)
- Corresponding author
- Temraz, Sally
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2015-09-23
- Volume
- 16
- Issue
- 9
- Pages
- 22976-22988
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4613347
- OpenAlex
- W2120687938
- Cited by
- 117
- References
- 55
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 2 · 2021: 9 · 2020: 13 · 2019: 15 · 2018: 19 · 2017: 16 · 2016: 10
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- colorectal cancer, MEK inhibitors, PI3K signaling, KRAS mutation, BRAF mutation, MAPK signaling, PI3K/mTOR inhibitors, drug resistance, Wnt signaling, PIK3CA, Akt, IGF-1 receptor, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Colon, Humans, Mutation, Rectum, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Mitogen-Activated Protein Kinase Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.